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Introduction: Assessment of lymph node status is a critical issue in 
the surgical management of non–small-cell lung cancer (NSCLC). 
We sought to determine the prognostic value of metastatic lymph 
node ratio (LNR) in patients with radical surgery for NSCLC.
Methods: We abstracted data from 480 consecutive patients under-
going radical surgery for NSCLC between 2006 and 2008 in our 
institution. Kaplan–Meier estimated the survival function using the 
number of metastatic lymph node (MLN) and LNR as categorized 
variables. The prognostic value of age, sex, smoking status, location 
of tumor, histology, pathology T stage, pathology N stage, surgi-
cal procedure, chemotherapy, MLN, and LNR were assessed using 
a multivariate Cox proportional hazards model for overall survival 
(OS) and disease-free survival (DFS).
Results: The median numbers of examined lymph nodes and MLNs 
were 15 and 5, respectively. Optimal cutpoints of the LNR were cal-
culated as 0, 0 to 0.35, and greater than 0.35. Patients with higher 
LNR were associated with worse OS and DFS in the whole series, 
whereas there was no significant difference in the OS and DFS of 
those patients classified as pathology N2. A multivariate analysis 
showed that the LNR staging, smoking status, and chemotherapy 
were revealed to be independent prognostic factors.
Conclusions: LNR is an independent predictor of survival in patients 
with NSCLC undergoing radical resection; the prognostic signifi-
cance is more valuable in patients classified as pathology N1.
Key Words: Prognostic, Metastatic lymph node, Lymph node ratio, 
Non–small-cell lung cancer.
(J Thorac Oncol. 2013;8: 429-435)
Non–small-cell lung cancer (NSCLC) remains a major cause of cancer death, and the 5-year survival rate is 
still poor despite early detection and therapeutic modalities.1 
Among the known prognostic factors, lymph node (LN) sta-
tus is currently regarded as the strongest prognostic parameter 
for patients with NSCLC. The nodal staging in the current 
seventh edition of the tumor, node, metastasis (TNM) clas-
sification is defined based on the anatomical location of posi-
tive LNs, as in the previous sixth edition; however, the TNM 
classification system for breast, gastric, and colorectal can-
cers has been updated from the traditional system to include 
number of metastatic lymph nodes (MLN) in the N staging.2 
The prognostic value of MLNs on survival for patients with 
NSCLC has long been focused by several studies3–5; however, 
the maximal number of MLNs is limited by the number of 
LNs sampled, and it is difficult to assess the LN status reliably 
without removing sufficient numbers of LNs. The lymph node 
ratio (LNR), defined as the ratio of positive LNs divided by 
the total number of retrieved LNs, reflects both the parameters 
and has been shown to represent a powerful independent prog-
nosticator in several solid cancer types.6–9 For NSCLC, two 
recent reports from America have, respectively, demonstrated 
that increasing LNR is a significant prognostic indicator for a 
worse survival in pathology N1 (pN1) patients according to 
different age groups.10,11 In this retrospective study, we aimed 
to further evaluate the importance of LNR as a prognostic fac-
tor on the survival of patients with resectable NSCLC and to 
compare its prognostic power against other methods, such as 
the traditional pN staging and the number of MLNs resected.
PATIENTS AND METHODS
Patients and Pretreatment Evaluation
We reviewed the records of 532 patients with NSCLC 
who underwent major pulmonary resection and system-
atic node dissection of the hilar and mediastinal LNs at our 
institute between 2006 and 2008. Patients who had small-
cell carcinoma, concomitant double cancer, pathological Tis 
disease, and stage IV disease were excluded from this study. 
Ultimately, a total of 480 patients were enrolled.
All patients underwent physical examination; computed 
tomography (CT) or magnetic resonance imaging of the brain, 
chest, and abdomen; and emission CT of bone preoperatively 
to make a definite diagnosis and make sure that there was 
no metastasis. Positron emission tomography was rarely 
implemented during this study period. Bronchoscopy was 
routinely performed to obtain a pathological diagnosis by 
transbronchial lung biopsy and to evaluate endobronchial 
staging.
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Treatment
The enrolled patients underwent lobectomy, bilobec-
tomy, or pneumonectomy. A complete mediastinal lymph-
adenectomy was routinely performed. After surgery, en bloc 
dissected tissues were separated into each LN precisely. All 
resected specimens, including the primary tumor and resected 
hilar and mediastinal LNs, were examined to determine 
both the tumor histology and the extent of LN metastases. 
Pathological staging was based on the current seventh edi-
tion of the TNM classification. The main adjuvant treatment 
that patients underwent after operation was chemotherapy or 
radiotherapy. A total of four to six cycles of chemotherapy 
was administered to 261 patients (56%).The chemotherapy 
was a routine program for NSCLC according to the National 
Comprehensive Cancer Network.
Follow-Up
Follow-up information was obtained from all patients 
through office visits or telephone interviews with the patient, 
with a relative, or with their primary physicians and were 
evaluated by chest roentgenography, chest CT scans, and bone 
scintigraphy. Patients were followed up every 3 months for 1 
year after operation, every 6 months for 3 years, and every 
year thereafter, with a median follow-up period of 37 months 
(range, 2–65 months). A total of 480 patients were followed 
up until death or the last day of follow-up (June 15, 2011). 
The overall survival (OS) in each patient was defined as the 
interval between the date of the definitive resection and the 
date of the last follow-up or death, and disease-free survival 
(DFS) was defined as the time interval between the date of the 
definitive resection and detection of first disease recurrence, 
metastasis, or the date of the last follow-up.
Statistical Analyses
Medical records and survival data were obtained from 
all patients. For the MLN and LNR, the “optimal” cutoff val-
ues were determined using χ2 scores, which were calculated 
using the Cox proportional hazards regression model. The 
Kaplan–Meier method was used to plot the survival curves, and 
the log-rank test was used to evaluate the differences among the 
subgroups. Multivariate analysis of several prognostic factors 
was performed with Cox proportional hazards regression model. 
Factors with a p value of less than 0.1 in the univariate analy-
sis were included in the multivariate analysis. Receiver operat-
ing characteristic (ROC) curves and the areas under the curves 
(AUC) were calculated for the three staging systems (LNR stag-
ing, MLN staging, and pN staging) to assess the accuracy of 
their predictive ability. A p value of less than 0.05 was consid-
ered to be statistically significant. All statistical analyses were 
performed using SPSS (version 17.0; SPSS Inc, Chicago, IL).
RESULTS
Patients’ Characteristics
A retrospective series of 480 patients with NSCLC 
(352 men, 128 women; median age: 59 years; range, 34–84 
years) was retrieved from the original files of the Department 
of Thoracic Surgery of Shandong Provincial Hospital for the 
study. Overall, 7307 LNs were removed from the patients, 
and there were 1149 involved nodes. The median number of 
removed nodes was 15, with the median number of positive 
nodes being five (Table 1). The number of the MLN was sig-
nificantly correlated to the LNR (r =0.751; p < 0.001) (Fig. 1).
Cutoff Values for the MLN and LNR
The optimal cutoff of MLN and LNR were analyzed by 
the Cox proportional hazards regression model. Based on the 
maximal χ2 score, the optimal cutoff value was three nodes for 
the number of MLNs (Table 2) and 35% for LNR (Table 3). 
TABLE 1.  Patient Characteristics
Variable no. of patients Percent
gender
 Male 352 73.3
 Female 128 26.7
Age
 <60 yr 295 61.5
 ≥60 yr 185 38.5
Smoking status
 Smoked 303 63.1
 Never smoked 177 36.9
Location of tumor
 Left 228 47.5
 Right 252 52.5
Histological diagnosis
 Adenocarcinoma 232 48.3
 Squamous cell 212 44.2
 Large cell 9 1.9
 Others 27 5.6
pT stage
 T1 171 35.6
 T2 230 47.9
 T3 79 16.4
pN stage
 N0 254 52.9
 N1 115 24.0
 N2 111 23.1
Surgical procedure
 Lobectomy 376 78.3
 Bilobectomy 44 9.2
 Pneumonectomy 60 12.5
Chemotherapy
 Yes 269 56.0
 No 211 44.0
Metastatic lymph node
 0 254 52.9
 1–3 118 24.6
 ≥4 108 22.5
Lymph node ratio (%)
 0 254 52.9
 0–35 153 31.9
 >35 73 15.2
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Based on these results, both the MLN and LNR were placed 
into one of three categories in subsequent analyses (0, 1–3, or 
≥4 and 0, 0–35% or >35%, respectively).
Impact of MLN Staging and pN Staging 
on OS and DFS after Resection
The median number of MLNs was five (range, 1–51). 
Of the 480 assessable patients, 254 patients (52%) were 
classified as N0, 115 patients (24%) were classified as N1, and 
111 patients (23%) were classified as N2. The Kaplan–Meier 
survival curves for OS and DFS are depicted in Figs 2 and 
3. In the whole series, patients with more MLN(s) removed 
and more advanced pN staging have worse OS and DFS (p < 
0.0001).
Prognostic Value of LNR for OS 
and DFS after Resection
Survival analysis indicated that a higher LNR group 
was associated with worse OS (p < 0.0001) (Fig. 4A) and DFS 
(p < 0.0001) (Fig. 4B). The pN classification according to the 
Union for International Cancer Control (UICC)/TNM, how-
ever, showed an imbalance in prognostic separation. There was 
no significant difference in the OS and DFS of those patients 
FIGURE 1.  Correlation between metastatic lymph node 
(MLN) and lymph node ratio (LNR).
TABLE 2.  Analysis of the Number of Positive Lymph Nodes 
Using the Cox Proportional Hazards Regression Model
Cutoff value for positive node number χ2 score p Value
0, 1, ≥2 32.7 0.000
0, 1–2, ≥3 36.0 0.000
0, 1–3, ≥4 39.2 0.000
0, 1–4, ≥5 37.4 0.000
0, 1–5, ≥6 34.7 0.000
TABLE 3.  Analysis of the Lymph Node Ratio (LNR) 
Calculated by the Cox Proportional Hazards Regression 
Model
Cutoff value for LNR (%) χ2 score p Value
0, 0–5, >5 35.1 0.000
0, 0–10, >10 38.7 0.000
0, 0–15, >15 39.8 0.000
0, 0–20, >20 44.8 0.000
0, 0–25, >25 45.4 0.000
0, 0–30, >30 46.7 0.000
0, 0–35, >35 49.4 0.000
0, 0–40, >40 46.3 0.000
0, 0–45, >45 44.1 0.000
0, 0–50, >50 39.8 0.000
FIGURE 2. (A) Overall survival rates according to metastatic 
lymph node (MLN) in the whole series (log-rank χ2 = 42.7;  
p < 0.001). (B) Disease-free survival rates according to MLN 
in the whole series (log-rank χ2 = 52.6; p < 0.001).
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classified as pN2 as a function of LNR (Fig. 5C,D), whereas 
in patients classified as pN1, OS and DFS were significantly 
worse with higher LNR (p < 0.0001) (Fig. 5A,B).
Multivariate Analysis of Prognostic Factors
The number of MLNs (with the three-grade category) 
and the metastatic LNR (with the three-grade category) 
were evaluated, along with other potential prognostic 
factors (including sex, age, smoking status, tumor location, 
histological type, pT category, pN category, surgical procedure, 
and chemotherapy), for the prognostic significance in the 
multivariate analysis using Cox proportional regression hazard 
model. The results of multivariate analyses are presented 
in Table 4. pN stage was one of the significant prognostic 
factors, when the LNR was not included in the analysis (data 
not shown). However, when the LNR-based classification was 
included in the model as a covariate, LNR, smoking status, 
and chemotherapy were revealed to be independent prognostic 
factors for OS and DFS, and pN stage lost its significance.
Comparison of the Predictive Ability of 
the Three Staging Systems Based on LN
The ROC curves were used to compare the three afore-
mentioned N staging systems, and the AUC were calculated 
to assess the accuracy of each system’s predictive ability 
for patients with NSCLC who underwent radical resection 
(Fig. 6). The AUC was 0.678 for LNR staging, 0.665 for MLN 
staging, and 0.672 for the seventh edition of UICC N staging. 
The 95% confidence interval for the three AUCs are crossed, 
suggesting that there was no statistical significance among the 
three staging methods.12
FIGURE 3.  (A) Overall survival rates according to pN in the 
whole series (log-rank χ2 = 47.2; p < 0.001). (B) Disease-free 
survival rates according to pN in the whole series (log-rank  
χ2 = 60; p < 0.001).
FIGURE 4.  (A) Overall survival rates according to lymph 
node ratio (LNR) in the whole series (log-rank χ2 = 54.1;  
p < 0.001). (B) Disease-free survival rates according to LNR  
in the whole series (log-rank χ2 = 59.7; p < 0.001).
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DISCUSSION
Adequate assessment of the nodal status is a critical 
issue in the surgical management of patients with lung cancer. 
In the latest TNM classification,2 the nodal system in lung 
cancer is still based on the anatomical location of involved 
LNs. However, there is also growing evidence establishing 
the prognostic role of the number of MLN and LNR in 
NSCLC.5,11,13–15
FIGURE 5.  (A and B) Overall survival (OS) and disease-free survival (DFS) rates according to lymph node ratio (LNR) in pN1 
NSCLC. (C and D) OS rate and DFS rates according to LNR in pN2 NSCLC. NSCLC, non–small-cell lung cancer.
TABLE 4.  Prognostic Factors for OS and DFS Retained in a Multivariate Analysis of 480 Patients with NSCLC
Variables OS DFS
HR (95% CI) p Value HR (95% CI) p Value
LNR 0.000 0.000
 0 1 1
 0–0.35 0.249 (0.159–0.389) 0.318 (0.212–0.477)
 >0.35 0.422 (0.277–0.643) 0.570 (0.390–0.833)
Smoking 1.614 (1.111–2.346) 0.012 1.347 (0.977–1.857) 0.069
Chemotherapy 0.542 (0.376–0.781) 0.001 0.444 (0.321–0.615) 0.000
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; LNR, lymph node ratio; OS, overall survival.
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Fukui et al.4 first analyzed the number of MLNs in 
resected NSCLC and suggested that the MLNs is a strong 
independent prognostic factor in NSCLC; they revealed the 
5-year survival of patients with seven or more metastatic LNs 
to be 6%, which was significantly worse than n4–6 patients 
(5-year survival: 42%), n1–3 patients (5-year survival: 58%), 
or n0 patients (5-year survival: 77%). The present results 
also indicate that improved survival outcomes are associated 
with a less number of MLNs for various tumor histologies. 
In support of our study, Lee et al.15 reviewed 1081 patients 
who underwent major pulmonary resection between 1990 and 
2006 and found the number of MLNs proved to be a good 
prognostic factor in NSCLC. According to the study by Wei 
et al.5, MLN shown to be a better prognostic determinant than 
the location-based pN stage.
Along with the number of MLN, another related measure 
is LNR, which has been identified as a significant prognostic 
value in breast cancer,8 pancreatic cancer,16 gastric cancer,17 
and colon cancer.6 In an examination of 651 Japanese patients 
with NSCLC, Matsuguma et al.13 showed that LNR was a sig-
nificant prognostic factor and showed superiority to the UICC 
classification with respect to the location of metastatic LNs. 
In another American study, Nwogu et al.18 analyzed 25,887 
patients with NSCLC from the SEER database to determine 
the influence of LNs examined and LNR on survival and 
found more LNs resected and lower LNR are associated with 
better patient survival independent of age, sex, grade, tumor 
size, and stage of disease.
There is, however, no clear consensus about the cutoff 
point of the staging classification. In a few articles related 
to our study, Matsuguma et al. divided the LNRs into three 
categories (0, 0.01–0.12, or ≥0.12) according to the median 
number of 11.1% for node-positive patients. In another study 
considering the N1 NSCLC, they divided the LNR into three 
categories (<0.15, 0.15–0.5, and >0.5) based on previous 
studies on other types of tumors and on the distribution of 
the LNR in the Surveillance, Epidemiology and End Results 
database. The current study used χ2 scores calculated by 
the Cox proportional hazards regression model and thus 
determined the cutoff value to be three positive nodes for 
MLN and 0.35 for LNR.
Based on the three categories, we found that a higher 
LNR group was associated with a worse OS and DFS in the 
whole series, which was also shown to be an independent factor 
for OS and DFS. We also investigated the impact of the LNR 
on survival rates according to pN staging system, the trend 
mentioned above can only be seen in pN1 patients. The ben-
efits of adjuvant chemoradiotherapy for early-stage NSCLC 
remain controversial. Despite the significant role of staging 
in predicting survival, the prognosis may differ according to 
the number, level, or type of LNs involved. Patients with N1 
NSCLC are a heterogeneous group in terms of survival and 
often do not get adjuvant chemotherapy despite an estimated 
33 to 60% risk of disease-related death within 5 years of diag-
nosis.19–21 Our results showed that patients with a higher LNR 
seem to be at an increased risk of recurrence, which is also 
consistent with the findings of two recent studies evaluating 
the relationship between the LNR and survival for N1 patients 
with NSCLC.3,10 These data could provide useful prognostic 
information to physicians and patients, allowing the selection 
of patients for more aggressive postoperative therapy or closer 
follow-up strategy.
To date, a number of studies have shown that LNR 
staging can be an alternative to the pN staging in breast, 
pancreatic, and stage III colon cancers8,16,22. The multivariate 
analysis in our study also showed that when the LNR-based 
classification was included, pN stage lost its significance, and 
LNR, smoking status, and chemotherapy were revealed to be 
independent prognostic factors for OS and DFS. From the 
ROC curve, we still cannot reach the conclusion that LNR 
staging has superiority than the pN staging in NSCLC. The 
combination of the LNR and pN status provides a valuable 
help with prognosis.
In summary, the current study demonstrates that LNR is 
an independent predictor of survival in patients with NSCLC. 
Moreover, we found that LNR is more informative toward pre-
dicting survival in pN1 stage patients.
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